WHO Updates TB Treatment Guidelines For Drug-Resistant Strains, Recommends All-Oral Regimen

Health Policy Watch: WHO Recommends Worldwide Adoption Of All Oral Regimen For MDR/RR-TB
“The World Health Organization issued new guidelines for the treatment of multi drug-resistant (MDR) tuberculosis on Wednesday, prioritizing for the first time an all-oral treatment regimen. The new treatment recommends replacing the painful injectable drugs that patients had to endure under previous treatment guidelines with a shorter course of oral bedaquiline — one of only three new drugs approved for treatment of TB within the last half century…” (Ren, 12/13).

Science Speaks: WHO recommends expanded access to new, shorter, all oral regimens for drug-resistant TB
“…Among the data leading to the updated recommendation, released in a WHO Rapid Communication Thursday, was data from South Africa’s TB program showing that replacing the injected medicine with bedaquiline — approved in 2012 by the U.S. Food and Drug Administration to treat drug resistant TB and still one of the newest tuberculosis treatment medicines — led to better patient outcomes and less loss to follow up care…” (Barton, 12/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.